Author: Raj Dombe

Compounded Topical Drug Market Companies and Developments Announcements

The compounded topical drug market was estimated at US$ 4.27 billion in 2023 and is projected to grow to US$ 6.78 billion by 2034, rising at a compound annual growth rate (CAGR) of 4.29% from 2024 to 2034. The demand for personalized medicines and the increasing incidence of skin disorders drive the market.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5317

Compounded Topical Drug Market: Customized Care

Compounded drugs are sterile or nonsterile drugs or nutrients formulated in a licensed pharmacy, outsourcing facility, or other healthcare-related facility. They are not FDA-approved for safety and effectiveness. Compounding involves combining, mixing, or altering ingredients tailored to the needs of the patients. According to the American Chronic Pain Association, the most common compounded medications are topical medications. Topical drugs are semisolid preparations or transdermal patches on the skin, mucous membranes, or cavities. Topical preparations treat pain for injured workers with a specific need. Topical agents are often prepared by mixing the powdered tablet in a petroleum base to form ointments.

The increasing incidences of skin disorders potentiate the demand for compounded topical drugs. According to the WHO, 1.8 billion people are estimated to be affected by skin conditions at any point in time. The demand for personalized medicines and the ease of preparation of topical drugs boost the market. If a person is allergic to any dye or ingredient, compounded preparations can be made without the dye or ingredient. The market is also driven by increasing drug shortages due to rising population and demand.

Trends in the Compounded Topical Drug Market

In May 2022, Medisca, a leading supplier of pharmaceutical compounding products, acquired DIFFUSIMAX and DIFFUSIMAX10 liposomal bases from Maxima Pharmaceuticals. These products are used in preparing compounded topical formulations and include all intellectual property assets from Maxima.

In April 2022, the U.S. FDA added four substances to its 503B Bulks List, which includes APIs determined to be necessary for compounding by outsourcing facilities. The new APIs added are diphenylcyclopropenone, glycolic acid, squaric acid dibutyl ester, and trichloroacetic acid, all for use in topical formulations.

Calgary Co-op’s 2023 sales were reported at approximately $1.3 million, marking a $0.1 million increase from 2022, with net earnings of $16,704.

Automation: The Future of the Compounded Topical Drug Market

Recent advancements in technology, such as artificial intelligence (AI), are transforming the compounding process by introducing automation. This shift improves efficiency, accuracy, and safety. Traditional pharmacy compounding is a labor-intensive process requiring careful human input, but AI-powered systems can automate the entire procedure, streamlining workflows and reducing the risk of errors.

AI can enhance precision by accurately measuring and dispensing ingredients, as well as enabling real-time monitoring to identify and correct mistakes early on. This automation not only helps minimize human errors but also frees up time for pharmacists to focus on patient care and medication counseling, leading to improved health outcomes.

Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/compounded-topical-drug-market-sizing

To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5317

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

Human Coagulation Factor VII Market Companies and Developments

The global human coagulation factor VII market size was estimated at US$ 1.21 billion in 2023 and is projected to grow to US$ 1.82 billion by 2034, rising at a compound annual growth rate (CAGR) of 3.74% from 2024 to 2034. Human coagulation factor VII is used to prevent bleeding, and growing cases of accidents and trauma are increasing the demand for coagulation factor VII.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5300

Human Coagulation Factor VII Market Overview

Human coagulation factor VII is a critical clotting agent used to prevent excessive bleeding, particularly in individuals with hemophilia. This condition can lead to life-threatening bleeding during surgeries or following trauma and accidents. In such cases, external doses of coagulation factors like factor VII are needed to manage bleeding. As the incidence of hemophilia increases and more surgeries are performed globally, the demand for human coagulation factor VII is expected to rise.

Market Trends

In August 2024, the U.S. Food and Drug Administration (FDA) resolved a shortage of the 8-milligram vial of Novo Nordisk’s NovoSeven RT coagulation factor VIIa (recombinant), which had been ongoing since February 2024.

Additionally, in March 2024, TiumBio Co., Ltd. filed a Clinical Trial Application (CTA) with the Spanish and Italian Medicines Agencies to begin a Phase 1b study for TU7710, a novel recombinant activated factor VII (rFVIIa) aimed at treating hemophilia patients with inhibitors.

Market Opportunity: Growing Geriatric Population

The increasing elderly population is another key factor driving the growth of the human coagulation factor VII market. Older individuals are more likely to undergo surgeries due to age-related health issues. As factor VII plays a crucial role in preventing excessive bleeding during surgeries, the growing number of older patients will contribute to the rising demand for this product.

Challenges Facing the Human Coagulation Factor VII Market

Despite its importance, factor VII treatments are often expensive, which may limit access for patients, particularly in low-income countries. The complex regulatory process and long approval times for new treatments can also delay the availability of new products. Additionally, the potential side effects of factor VII therapies may discourage some patients and healthcare providers from choosing this treatment.

Regional Insights

North America led the human coagulation factor VII market in 2023. This is largely due to the region’s high number of surgeries, strong government support, a growing healthcare and pharmaceutical industry, and active blood donation initiatives that ensure a steady supply of coagulation factors. The U.S. and Canada are major contributors to market growth, with the U.S. holding the largest share.

For instance:

• In the U.S., approximately 33,000 men have hemophilia, and around 3,442 Canadians were diagnosed with Hemophilia A in 2022.
• Surgical expenses account for over 25% of healthcare-related costs in the U.S. With around 40 to 50 million major surgeries performed annually in the U.S. and 20 million in Europe, the demand for coagulation factor VII remains high.

Asia Pacific is expected to experience the fastest market growth during the forecast period, driven by an expanding population and an increasing number of surgeries. Coagulation factor VII is crucial for preventing excessive bleeding during surgeries, further boosting its demand in the region.

For example:

• By 2050, the elderly population in India is projected to grow significantly, reaching over 20% of the total population.
• In 2023, China had over 297 million people aged 60 or older, and this number is expected to surpass 500 million by 2050.
• In 2022, Chinese hospitals conducted approximately 82.7 million inpatient surgeries, with significant regional differences in surgical volume.
• India, with an estimated 30 million surgeries annually, will also see an increased demand for coagulation factors, especially given the country’s large population and high surgical procedure rates.

Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/human-coagulation-factor-vii-market-sizing

To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5300

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

Thrombopoietin Receptor Agonists Market Size Shares and Trends

The global thrombopoietin receptor agonists market, valued at $1.85 billion in 2023, is projected to reach $3.74 billion by 2034, with a CAGR of 6.6%. Demand is driven by these drugs’ role in boosting platelet counts to reduce health risks.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5297

Healthcare and Medical Simulation Market Size and Future Directions

The healthcare and medical simulation market was valued at US$ 2.14 billion in 2023 and is expected to expand to US$ 7.04 billion by 2034. This growth represents a compound annual growth rate (CAGR) of 11.44% from 2024 to 2034. Key factors driving this market include technological advancements, increasing demand for patient safety, and the need for high-quality treatment.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5310

Healthcare and Medical Simulation Market: Revolutionizing Healthcare

Healthcare simulation, or medical simulation, is an innovative approach to training and educating healthcare professionals in mastering cognitive, technical, and behavioral skills through advanced technologies. The primary objectives of healthcare simulation include education, assessment, research, and health system integration, all aimed at enhancing patient safety. By mimicking real-life scenarios and processes, healthcare simulations allow professionals to build skills and confidence without the risk of harming patients or delaying necessary treatments. Simulation centers are designed to elevate quality and ensure patient safety.

Medical simulation provides a host of benefits, such as reducing medical errors, fostering team communication, and enhancing crisis resource management skills. The growing emphasis on minimizing errors and improving patient outcomes has fueled the demand for medical simulation. Students receive hands-on training and can apply theoretical knowledge in a practical setting, thereby improving their decision-making abilities and responsiveness in emergencies.

Healthcare and Medical Simulation Market Trends

In August 2024, HCA Healthcare announced a $500,000 grant to Nova Southeastern University (NSU) to establish a clinical simulation lab supporting its new nurse anesthesiology program. This funding will equip nursing students with state-of-the-art technologies for training in the dynamic healthcare landscape.

In January 2024, Oxford Medical Simulation (OMS) successfully completed a $12.6 million Series A funding round to transform healthcare education, training, and assessment.

Also in January 2024, GigXR, Inc. collaborated with CAE Healthcare to enhance the efficiency and effectiveness of clinical simulation. This partnership aims to implement and manage multimodal simulation for medical and nursing schools, hospital systems, first responders, and governmental agencies.

Virtual Reality and Augmented Reality: The Future of Healthcare and Medical Simulation

The rise of advanced technologies such as artificial intelligence (AI), virtual reality (VR), and augmented reality (AR) is transforming the simulation landscape. VR allows students to experience visual stimuli through computer graphics, while AR enhances real-world environments with virtual elements. These technologies enable learners to practice various procedures involving the human body without needing a live patient, improving their overall performance and decision-making capabilities. AR and VR provide tailored training opportunities based on individual progress, streamlining the healthcare training ecosystem.

Challenges: High Costs and Shortage of Trained Professionals

Despite its benefits, the healthcare simulation market faces challenges, primarily the high costs associated with simulation training, which limits accessibility for low- and middle-income countries (LMICs). This situation often leads to inadequate training for professionals in smaller healthcare facilities. Additionally, there is a significant shortage of trained professionals capable of delivering effective simulation training.

Regional Insights

North America: Dominance Driven by Tech Innovation and Key Players

In 2023, North America held a substantial share of the healthcare and medical simulation market. The region’s market is propelled by the presence of leading companies, technological advancements, and an abundance of skilled professionals. The implementation of medical simulation techniques is heavily influenced by major players in the U.S., alongside supportive government policies. The Agency for Healthcare Research and Quality (AHRQ) plays a pivotal role by investing in research to optimize simulation use in healthcare. As of 2023, there are 1,114 simulation centers registered in the U.S. and Canada, with 415 centers accredited.

Asia-Pacific: Favorable Government Policies Fueling Growth

The Asia-Pacific region is expected to exhibit the fastest growth in the healthcare and medical simulation market over the forecast period. Rapid technological advancements, increased investments, collaborations, and supportive government policies are driving this market’s expansion. Research and development efforts to assess the effectiveness of simulation systems are also increasing. Several governmental initiatives promote the establishment of simulation labs and centers in the region. For example, the Japanese government partnered with the WHO to enhance health emergency readiness in Pacific Island countries through workshops and emergency simulation exercises.

In April 2023, India launched the DiShA platform (Digital Shiksha for Advanced Clinical Capacity Building) at Amrita Hospital, marking the country’s first case-based simulation learning platform focused on critical care in public health.

Segmental Insights

• By Product and Services: The anatomical model segment dominated the global healthcare and medical simulation market in 2023, with expected rapid expansion due to the demand for detailed representations of human anatomy in healthcare institutions and medical schools.
• By Technology: The procedural rehearsal technology segment maintained a dominant position in 2023, as it is particularly effective for rehearsing complex procedures or surgeries that are infrequently performed, significantly enhancing operative performance and reducing errors.
• By End-Use: The academic institutions segment led the market in 2023, driven by an increasing number of medical students and supportive infrastructure. Conversely, the hospital segment is projected to grow the fastest, attributed to significant capital investments and a rising number of interns seeking advanced medical training.

Recent Developments in the Healthcare and Medical Simulation Market

In July 2024, Mercer University School of Medicine (MUSM) and SGMC Health inaugurated a clinical campus and simulation lab in Valdosta, Georgia, tailored for third- and fourth-year students to fulfill essential clerkships, sub-internships, and electives.

In May 2024, Sheikh Shakhbout Medical City in Abu Dhabi opened its Centre of Innovation and Medical Simulation to provide advanced training for healthcare professionals, including doctors, nurses, allied health workers, and medical students.

Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/healthcare-and-medical-simulation-market-sizing

To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5310

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

Acne Medicine Market Size, Share, and Regional Insights

The global acne medicine market, valued at US$ 13.44 billion in 2023, is projected to reach US$ 23.33 billion by 2034, with a CAGR of 5.14% from 2024 to 2034. This growth is driven by the rising prevalence of skin conditions due to factors like poor diet, lack of exercise, and hormonal imbalances, leading to increased demand for innovative treatments.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5309

Regional Insights

In 2023, North America led the acne medicine market, driven by a high incidence of acne among Americans and ongoing innovations in acne treatments. The American Academy of Dermatology reports that acne is the most common skin condition in the U.S., affecting up to 50 million individuals annually. Additionally, the increasing focus on personal skincare and grooming is significantly boosting the market.

In the U.S. and various other countries, advancements in acne treatment products emphasize minimal side effects and enhanced efficacy, thanks to extensive research and development. Consumers are increasingly investing in high-quality products that deliver effective results. The U.S. Centers for Disease Control and Prevention (CDC) offers educational resources and guidelines on antibiotic use for acne treatment.

The American Academy of Dermatology provides clinical management guidelines for acne vulgaris, catering to both adults and adolescents, based on insights from U.S. and Canadian dermatologists. These guidelines include recommendations for topical medications and combination therapies.

In the Asia Pacific region, rapid growth in the acne medicine market is attributed to the rising adoption of AI-enabled telemedicine in China, which is transforming dermatological care by enhancing treatment accessibility and personalized care. AIDERMA, China’s first platform for AI-assisted diagnosis and therapy for skin conditions, provides consultations, education, and support for over 90 common skin diseases.

In China, government financing supports the Urban Employee Basic Medical Insurance and the Urban Rural Resident Basic Medical Insurance, covering hospital treatments, prescription medications, and both general and specialty care for various demographics, including self-employed individuals and children. More than 7,000 clinicians are registered with AIDA, an app that helps doctors diagnose conditions like eczema, psoriasis, and atopic dermatitis.

The Health Sciences Authority of Singapore oversees regulatory requirements for cosmetic and health safety products, emphasizing the importance of good manufacturing practices and adverse event reporting. Additionally, the National Medical Products Administration (NMPA) in China has approved a phase II clinical trial for ASC40, aimed at evaluating the treatment’s effectiveness and safety in patients with moderate to severe acne.

Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/acne-medicine-market-sizing

To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5309

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5307

The global plasma fraction market was valued at approximately USD 32.75 billion in 2023 and is forecasted to reach USD 72.86 billion by 2034, representing a compound annual growth rate (CAGR) of 7.54% from 2024 to 2034.There is a rising demand to create medicine products derived from plasma to treat rabies, tetanus, shock, and trauma. This factor is owing to the growth of the plasma fraction market.

High Cost of Products Impeding Market Growth

Despite the life-saving benefits of plasma and its derived proteins, the high cost of plasma-derived medicinal products (PDMPs) is hindering market growth. Rising plasma prices have directly affected the sustainability of PDMP production. During the pandemic, many countries experienced shortages of immunoglobulin, leading to rationing for patients with critical illnesses. Even in nations like Germany and the United States, where commercially sourced plasma availability is relatively high, a shortage has been noted due to surging demand for PDMPs. Over the last five years, the cost of plasma per liter has risen by 59.3% in Europe and 40.7% in the United States.

Regional Insights

In 2023, North America dominated the plasma fraction market, driven by an increase in plasma exports from the region. The United States is the world’s leading exporter of plasma, accounting for approximately 70% of global plasma supplies. This significant contribution has allowed the U.S. to collect the majority of the world’s plasma for PDMP production, generating a staggering $37 billion in blood product exports in 2023. As global demand for plasma continues to grow, the pressure on the U.S. to extract and export more plasma intensifies.

Europe is anticipated to experience the fastest growth during the forecast period, primarily due to stringent regulations and rising plasma shortages. Many European countries now rely on imports to satisfy their medical needs. Notably, just four countries—Austria, Czechia, Germany, and Hungary—collect over 55% of the total plasma used for manufacturing in Europe.

In July 2024, the European Union implemented new regulations governing the quality and safety standards for substances of human origin intended for human use. This regulation, approved by the European Parliament, will take effect in May 2024.

Segmental Insights

By type, the immunoglobulins segment held the largest market share in 2023. Plasma-derived immunoglobulins are vital for treating autoimmune inflammatory diseases and play a crucial role in recovery following infections, such as COVID-19. They are often the sole treatment option for rare conditions like primary immunodeficiency.

The coagulation factors segment is expected to grow at the fastest rate during the forecast period, driven by their application in treating blood clotting disorders such as hemophilia and Von Willebrand’s disease.

By application, the hospital segment dominated the plasma fraction market, accounting for the largest share. This dominance is attributed to the use of plasma proteins in treating patients recovering from burns, trauma, animal bites, shock, major surgeries, hepatitis, RH incompatibility, organ transplants, pediatric HIV, and liver conditions.

The retail pharmacy segment is projected to grow at the fastest rate within the plasma fraction market, spurred by an increasing number of human donors providing sufficient plasma supplies. Additionally, a rising number of patients eligible for plasma-derived therapies will boost demand in the retail pharmacy sector.

Top Companies in the Plasma Fraction Market

• Baxter International
• Bayer
• Biotest
• BPL
• CBPO
• CSL Behring
• Fusion healthcare
• Grifols
• Kedrion Biopharma Inc.
• KM Biologics
• LBF USA
• LFB Group
• Nanyue Bio
• Octopharma
• RAAS
• Takeda Pharmaceuticals
• Tiantan Bio
• Weiguang Bio

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5304

Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/plasma-fraction-market-sizing

To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5304

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

Comparator Drug Sourcing Market and Leading Companies

The comparator drug sourcing market, valued at approximately USD 1.16 billion in 2023, is projected to grow to USD 2.24 billion by 2034, with a CAGR of 6.15% from 2024 to 2034. This growth is fueled by the increasing number of clinical trials, advancements in drug development, and rising investments in the industry.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5303

Comparator Drug Sourcing Market Trends

In July 2024, Catalent completed the expansion of its clinical supply facility in Schorndorf, Germany. This 32,000 sq. ft. facility offers comprehensive clinical supply services at controlled room temperatures between 15 and 25 degrees Celsius.

In April 2022, Yourway expanded its controlled ambient capabilities in Allentown, Pennsylvania, to meet the increasing demand for long-term, temperature-controlled storage, accommodating 5,000 pallets of clinical trial supplies.

McKesson Corporation reported consolidated revenue of $309 billion for fiscal 2024, reflecting a 12% increase from fiscal 2023. The company generated a cash flow from operations of $4.3 billion and a Free Cash Flow of $3.6 billion.

Artificial Intelligence: The Future of the Comparator Drug Sourcing Market

The emergence of advanced technologies is transforming the healthcare sector. Innovations like artificial intelligence (AI) and machine learning (ML) are streamlining the supply chain for comparator drugs. These technologies enable companies to quickly locate comparator suppliers based on specific products and geographic areas.

AI and ML can automate various aspects of the supply chain, including inventory management for comparator drugs and advanced tracking and monitoring systems. They also optimize logistics by identifying the most efficient shipping routes. Additionally, AI enhances temperature monitoring and control during transportation, ensuring drug quality.

Moreover, AI can mitigate risks associated with comparator drug sourcing, such as identifying subpar products, managing drug shortages, controlling excessive inventory, assessing supplier risks, and utilizing predictive analytics. Consequently, AI and other advanced technologies significantly enhance the resilience and efficiency of comparator drug sourcing.

Top Companies in the Comparator Drug Sourcing Market

• BAP Pharma
• Catalent, Inc.
• Cencora
• ClientPharma
• Clinigen
• Euromed Pharma
• McKesson Corporation
• Myonex
• NewLife Medicals, Inc.
• Sharp Services
• Thermo Fisher Scientific
• Yourway – The Biopharma Services Company

Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/comparator-drug-sourcing-market-sizing

To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5303

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare